agilon health's (AGL) "Sell" Rating Reiterated at Citigroup

agilon health (NYSE:AGL - Get Free Report)'s stock had its "sell" rating reissued by Citigroup in a report issued on Tuesday, Benzinga reports. They presently have a $2.50 price objective on the stock, down from their prior price objective of $7.00. Citigroup's target price indicates a potential downside of 0.79% from the company's current price.

Several other equities research analysts have also weighed in on the company. Bank of America lowered agilon health from a "buy" rating to an "underperform" rating and set a $3.00 target price on the stock. in a research report on Wednesday, October 2nd. Royal Bank of Canada reiterated an "outperform" rating and issued a $8.00 target price on shares of agilon health in a research note on Wednesday, August 7th. Benchmark reiterated a "buy" rating and issued a $9.00 target price on shares of agilon health in a research note on Thursday, August 8th. Evercore ISI cut their target price on agilon health from $7.00 to $4.00 and set an "in-line" rating on the stock in a research note on Tuesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft cut their price objective on shares of agilon health from $5.00 to $4.00 and set a "hold" rating on the stock in a research note on Friday, August 9th. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, agilon health currently has an average rating of "Hold" and a consensus target price of $7.81.

agilon health Stock Performance

AGL traded down $0.18 during trading hours on Tuesday, hitting $2.52. 3,569,472 shares of the stock were exchanged, compared to its average volume of 4,910,708. The stock has a 50-day simple moving average of $3.58 and a 200-day simple moving average of $5.13. agilon health has a 12 month low of $2.49 and a 12 month high of $18.37. The stock has a market cap of $1.04 billion, a price-to-earnings ratio of -3.60 and a beta of 0.54. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.36 and a quick ratio of 1.36.

agilon health (NYSE:AGL - Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). agilon health had a negative return on equity of 29.91% and a negative net margin of 5.57%. The firm had revenue of $1.48 billion for the quarter, compared to analysts' expectations of $1.56 billion. During the same period last year, the business posted ($0.04) earnings per share. The firm's revenue for the quarter was up 38.7% on a year-over-year basis. Analysts anticipate that agilon health will post -0.32 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Steven Sell purchased 20,000 shares of the company's stock in a transaction that occurred on Thursday, September 12th. The shares were purchased at an average price of $3.36 per share, with a total value of $67,200.00. Following the purchase, the chief executive officer now owns 67,590 shares of the company's stock, valued at $227,102.40. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 3.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On agilon health

Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in shares of agilon health by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 28,947,798 shares of the company's stock valued at $176,582,000 after buying an additional 371,537 shares in the last quarter. Capital International Investors grew its stake in shares of agilon health by 84.7% in the 1st quarter. Capital International Investors now owns 20,197,932 shares of the company's stock valued at $123,207,000 after buying an additional 9,263,296 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of agilon health by 3,338.5% in the 2nd quarter. AQR Capital Management LLC now owns 1,356,438 shares of the company's stock valued at $8,871,000 after buying an additional 1,316,990 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of agilon health by 18.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,108,921 shares of the company's stock valued at $7,252,000 after buying an additional 174,883 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC grew its stake in shares of agilon health by 65.0% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 804,594 shares of the company's stock valued at $5,262,000 after buying an additional 316,856 shares in the last quarter.

agilon health Company Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.